research Differential diagnoses of pseudolymphomatous folliculitis: considerations as regards one case
Accurate diagnosis of pseudolymphomatous folliculitis is crucial to avoid mistaking it for more serious conditions.
Search
for
Sort by
Research
990-1000 / 1000+ results research LUPUS AROUND THE WORLD Clinical and immunological manifestations in 151 SLE patients living in Dubai
SLE symptoms in Dubai are similar to those in other Arab and Western countries.
research Lichen planopilaris (LPP)
Treat active lichen planopilaris early to prevent permanent hair loss.
research 162 A review of the clinical and histopathological characteristics of patients with subepidermal blistering disorders presenting to a tertiary care centre in India
Most patients with blistering skin disorders in South India had bullous pemphigoid and often had other conditions like hypertension and diabetes.
research Lichen planopilaris
Lichen planopilaris is a chronic, scarring hair loss condition with no definitive cure, requiring accurate diagnosis and treatment to manage symptoms.
research LIVING WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN MAURITIUS: A NARRATIVE STUDY OF PATIENT EXPERIENCES
People with lupus in Mauritius face many challenges and need more support and understanding.
research LICHEN SCLEROSUS ET ATROPHICUS AND KRAUROSIS VULVAE
Lichen sclerosus et atrophicus is generally not considered precancerous, but there are exceptions.
research Pediatric Lichen: Epidemiological and Clinical Characteristics in Children
Pediatric lichen is rare and diverse, and dermoscopy helps improve diagnosis and management in children.
research Ulerythema Ophryogenes
Treatment with vitamin A did not improve the child's skin condition.
research SDRIFE Induced by Tofacitinib
A 19-year-old Indian woman with alopecia subtotalis was treated with tofacitinib, a Janus Kinase inhibitor, resulting in significant hair regrowth in 80% of patches within 1 month. However, she developed a pruritic symmetrical erythematous rash, diagnosed as symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), a rare cutaneous adverse effect. The rash, which began in the axilla and other flexural areas, intensified with continued medication use. Upon discontinuation of tofacitinib and treatment with topical corticosteroids, emollients, and oral antihistamines, the rash resolved. This case, reported to the Pharmacovigilance Programme of India, highlights the potential for SDRIFE as an adverse reaction to tofacitinib, classified as mild and probably preventable.